TUMOUR PROFILING FOR TRANSLATIONAL & CLINICAL RESEARCH
MERCURY’s intuitive interface enables users to quickly visualise an accurate and comprehensive molecular profile of tumours in cancer patients after rapid analysis of their sequencing data (tumour DNA and RNA plus constitutional DNA).
MERCURY also provides users with access to numerous annotation databases, links to potential clinical trials and treatment options based on the variants identified, as well as the ability to create and export a customisable report.
TRANSFORMING SEQUENCING DATA INTO KNOWLEDGE
MERCURY™ is now customisable for large and small gene panels
MERCURY is now fully adaptable to your data analysis needs with the ability to manage oncology sequencing data ranging from broad sequencing (WES, RNA-Seq, WGS) to large gene panels and even targeted gene panels. Whether you use a commercially available third party panel or have developed your own, IntegraGen will work with you to customise the data analysis and reporting pipeline for the clinical sequencing you perform.
MERCURY™ to identify difficult somatic mutations.
